CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Oncotest GmbH for $36.0 million, a transaction completed in November 2015, structured as all cash.
Oncotest GmbH operates in Discovery and Safety Assessment (DSA) — In Vivo Discovery, is based in Germany. Oncotest GmbH was a Germany-based CRO providing discovery services for oncology, with patient-derived xenograft (PDX) and syngeneic models.
The purpose of this acquisition was to expand our oncology services capabilities, enabling us to provide clients with access to a more comprehensive portfolio of technologies, including patient-derived xenograft (PDX) and syngeneic models. The preliminary purchase price for Oncotest was $36.0 million.
In Vivo Discovery business, DSA segment
In November 2015, we acquired Oncotest GmbH (Oncotest), a CRO providing discovery services for oncology, one of the largest therapeutic areas for biopharmaceutical research and development spending. The purpose of this acquisition was to expand our oncology services capabilities. The preliminary purchase price for Oncotest was $36.0 million.Charles River FY2015 10-K, Business Acquisitions note
Advisory firms were not disclosed for this transaction.